Monitoring Neoadjuvant Chemotherapy Responses with NIR Tomography

使用近红外断层扫描监测新辅助化疗反应

• 批准号: 8696209
• 负责人: SHUDONG JIANG
• 金额: $ 42.37万
• 依托单位: DARTMOUTH COLLEGE
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-03-25 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8696209
• 关键词: American College of Radiology Imaging Network; Biological Markers; Biopsy; Blood Vessels; Breast; Chemotherapy-Oncologic Procedure; Clinical; Clinical Oncology; Collaborations; Collagen; Complex; Data; Diffuse; Disease; Disease-Free Survival; Engineering; Enrollment; Feasibility Studies; Female breast; Flare; Frequencies; Funding; Future; Goals; Grant; Hand; Hemoglobin; Image; Image Analysis; In complete remission; Individual; Infusion procedures; Institution; Investigation; Laboratories; Lead; Length; Lesion; Lipids; Location; Magnetic Resonance Imaging; Mammary Neoplasms; Measures; Medical Oncology; Metabolism; Monitor; Near-Infrared Spectroscopy; Neoadjuvant Therapy; Optics; Outcome; Oxygen; Pathologic; Patients; Phase; Positioning Attribute; Prognostic Marker; Property; Randomized Clinical Trials; Recovery; Research Infrastructure; Research Personnel; Resected; Resolution; Scanning; Skin; Spectrum Analysis; Study Subject; Surface; Surgical Pathology; System; Technology; Testing; Time; Tissues; Translating; Tumor Burden; United States National Institutes of Health; Validation; Water; Woman; Work; base; cancer imaging; chemotherapy; cost; design; diffuse optical tomography; experience; improved; indexing; innovation; instrument; malignant breast neoplasm; neovascular; novel strategies; prognostic; public health relevance; response; spectroscopic imaging; tissue oxygenation; tomography; tool; treatment response; tumor

DESCRIPTION (provided by applicant): We hypothesize that a newly redesigned portable tomographic version of Near Infrared Spectroscopy (NIRS), developed and tested at Dartmouth over the past 15 years, can successfully characterize changes in breast tumor vascularity, and potentially cellular metabolism, more accurately and with higher spatial resolution than other NIRS technologies currently under investigation, and is better suited to clinical oncology workflow. NIRS tomography (NIRST) is a unique tool for characterizing tissue composition in the female breast which generates images of total hemoglobin concentration (HbT), tissue oxygen saturation (StO2), water fraction, as well as elastic scattering parameters. Based on results obtained in previous studies, the overall goal of this proposal is to develop and evaluate a portable and compact NIRST system that is expected to quantify changes in HbT, StO2 and water fraction more accurately as early indicators of treatment response of locally advanced breast cancers receiving neoadjuvant chemotherapy (NAC), and will have additional wavelengths enabling the recovery of new images of lipid and collagen content. Comparisons to results obtained with hand- held Diffuse Optical Spectroscopic Imaging (DOSI), which has undergone a recently-completed national multi- center (ACRIN) trial, will occur. The proposed mobile NIRST system will integrate into the workflow of clinical oncology practice to maximize patient accrual and participation in the proposed studies, assess the presence of a flair response, and determine whether prognostic information can be obtained that would influence patient management. After developing and validating the new portable NIRST platform with phantom and normal- subject studies, we will quantitatively assess our hypothesis by 1) imaging the response of tumor vasculature before, during and after infusions associated with different treatment cycles of NAC, and 2) quantify pathological and clinical outcomes of response to NAC, and relate these outcomes to changes in NIRST properties measured at different time points during NAC. The project will extend successful preliminary results obtained in studies supported through completed NIH P01 (P01-CA80139, PI Paulsen) and R21 (CA135303, PI Jiang) grants. It also leverages the extensive infrastructure we have developed for breast cancer imaging where investigators from medical oncology, surgical pathology and biomedical optical engineering have collaborated to develop and evaluate advanced technology for breast cancer imaging for more than a decade.

描述（由申请人提供）：我们假设，在过去15年中，在达特茅斯开发和测试的近期重新设计的便携式层析成像版本（NIRS）可以成功地表征乳腺肿瘤血管的变化，并且具有更准确的细胞代谢，并且比其他nir nirirs技术更准确地进行了较高的临床，并且具有更高的nir nirsoologies andirs nirsoologicy nirsoologices andoologies nirs技术，并且是较高的nirirs技术。工作流程。 NIRS断层扫描（NIRST）是表征女性乳房中组织组成的独特工具，该工具会产生总血红蛋白浓度（HBT），组织氧饱和度（STO2），水分分和弹性散射参数的图像。基于先前研究中获得的结果，该提案的总体目标是开发和评估一种可移植，紧凑的NIRST系统，该系统有望在接受NeoAdjuvant化学疗法（NAC）（NAC）的局部先进乳腺癌的早期治疗反应中更准确地量化HBT，STO2和水分分数的变化，并将为LIP恢复。与手工弥漫性光谱成像（DOSI）获得的结果进行比较（DOSI）将发生最近完成的国家多中心试验（ACRIN）试验。拟议的移动NIRST系统将集成到临床肿瘤学实践的工作流程中，以最大程度地提高患者应计并参与拟议的研究，评估天赋反应的存在，并确定是否可以获得预后信息，从而影响患者的管理。在通过幻影和正常学科研究开发和验证新的便携式NIRST平台之后，我们将通过1）成像在NAC的不同治疗周期和2）量化NAC的病理学和临床对NAC的响应时与NAC的响应相关的NAC和临床量相关的NAC量相对于NIRS的质量差异的时间差异而定量地评估肿瘤血管的响应。该项目将延长通过完整的NIH P01（P01-CA80139，PI Paulsen）和R21（CA135303，Pi Jiang）赠款支持的研究中获得的成功初步结果。它还利用了我们为乳腺癌成像开发的广泛基础设施，其中医学肿瘤学，外科病理学和生物医学光学工程的研究人员已合作开发和评估了十多年的乳腺癌成像的先进技术。